More From The Market Online
Pacific Edge’s APAC operations advancing towards profit with cancer test growth
Pacific Edge APAC business is advancing towards profitability on a direct-cost basis with a growing interest…
- Colin Sandell-Hay
- 3 mins
- 14 July 2026 09:44 (AEST)
Syntara shows encouraging first signals it can impact the path to Parkinson’s
Syntara (ASX:SNT) has reported encouraging interim results from its Phase 2 study of SNT-4728, providing the first clinical evidence
- Isaac McIntyre
- 2 mins
- 06 July 2026 12:34 (AEST)
Entropy reports 50% remission in Phase 2 psychedelic trial for binge eating disorder
Entropy Neurodynamics says its Phase 2 trial of TRP-8803 delivered 50% remission in all treatment-resistant binge…
- Seja Al Zaidi
- 2 mins
- 07 July 2026 13:30 (AEST)
Syntara reports encouraging early Parkinson’s trial results
Syntara has reported statistically significant reductions in brain inflammation in an early-stage Parkinson's disease study.
- Seja Al Zaidi
- 2 mins
- 06 July 2026 11:54 (AEST)
